4 Healthcare Stock Stories Prescribed for Investors

AstraZeneca Group (NYSE:AZN): Closing price $50.35

On Tuesday, the firm said that the United States District Court for the District of New Jersey ruled that its United States Patent No. 6,598,603, protecting Pulmicort Respules in the U.S., is invalid. Beyond that, the Court decided that the generic defendants involved in the litigation do not infringe AstraZeneca’s second patent, Patent No. 7,524,834. Executive Vice President, North America, Paul Hudson responed that “AstraZenca strongly disagrees with the Court’s decision. AstraZeneca has full confidence in the strength of its intellectual property rights protecting Pulmicort Respules. AstraZeneca is considering next steps, including an appeal of the Court’s decision.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AZN

Inovio Pharmaceuticals (AMEX:INO): Closing price $0.52

Inovio reports the release of preliminary clinical trial results by its collaborator ChronTech of their open label phase II clinical evaluation of ChronVac-C, which is ChronTech’s vaccine for the treatment of hepatitis C virus infection. The study investigated the use of the ChronVac-C DNA vaccine administered with Inovio’s MedPulser-DDS electroporation device followed by a drug regimen (ribavirin + PEG-interferon-a) in chronic HCV positive subjects. These initial results do not indicate a statistically significant difference thus far between treatment outcomes of the vaccinated and non-vaccinated groups. However, the vaccinated group did exhibit an excellent safety profile.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

INO

Thermo Fisher Scientific (NYSE: TMO): Closing price $78.56

Chatter has it that Thermo Fisher is number one in the bidding for Life Technologies. Shares of both firms moved higher Tuesday in reaction.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TMO

Affymax (NASDAQ:AFFY): Closing price $1.25

Shares closed down almost 8 percent Tuesday, after it was reported that net loss for the fourth quarter was $68.3 million, or $1.85 per share, compared year-over-year to a net loss of $29.4 million, or $0.82 per share, in 2011.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AFFY

Investing Insights: Is the New Abbot a Winner?